Pulse Biosciences, Inc.

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 17:20:31 23/01/2026 GMT			5-day change	1st Jan Change
14.90 ^USD	+2.41%		+5.61%	+9.61%

01-15	Pulse Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-09	Pulse Biosciences, Inc. Appoints Maria Sainz to Its Board of Directors, Effective January 9, 2026	CI

Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4)

Published on 11/21/2025 at 09:44 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Pulse Biosciences, Inc.

01-15	Pulse Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-09	Pulse Biosciences, Inc. Appoints Maria Sainz to Its Board of Directors, Effective January 9, 2026	CI
01-06	Pulse Biosciences Selects to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium	CI
12-19	Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4)	RE
12-18	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
12-18	Pulse Biosciences, Inc. Announces FDA Ide Approval to Initiate Its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation	CI
12-18	Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study	MT
12-18	Pulse Biosciences announces FDA IDE approval to initiate its nPulse cardiac catheter ablation system study	RE
12-09	Pulse Biosciences Initiates Research Collaboration for Thyroid Tumors Treatment Using nPulse Technology	MT
12-09	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with Npulse? Technology	CI
11-21	Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4)	RE
11-06	Pulse Biosciences, Inc., Q3 2025 Earnings Call, Nov 05, 2025
11-05	Pulse Biosciences Q3 net loss widens	RE
11-05	Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q3 Revenue $86,000	MT
11-05	Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
24/10/25	Pulse Biosciences, Inc. Announces First Enrollment in the NANOCLAMP AF Study	CI
10/10/25	Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system	RE
10/10/25	Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting	CI
17/09/25	Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
16/09/25	Pulse Biosciences Insider Sold Shares Worth $1,121,750, According to a Recent SEC Filing	MT
15/09/25	Pulse Biosciences Insider Bought Shares Worth $2,788,624, According to a Recent SEC Filing	MT
08/09/25	Pulse Biosciences Announces Fda Ide Approval to Initiate Its Nspfa Cardiac Surgery System Study for the Treatment of Atrial Fibrillation	CI
08/09/25	Pulse Biosciences Wins FDA Approval to Start Heart Surgery Study	MT
08/09/25	Pulse Biosciences announces FDA IDE approval to initiate its nsPFA cardiac surgery system study for the treatment of atrial fibrillation	RE
02/09/25	Pulse Biosciences, Inc. Announces First Successful Procedures in PRECISE Benign Thyroid Nodule Study	CI

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company